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Introduction. Pisa syndrome (PS) is a postural complication of Parkinson’s disease (PD). Yet, its pathophysiology remains unclear,
although a multifactorial component is probable. Cervical vestibular evoked myogenic potentials (cVEMPs) explore vestibu-
lospinal pathway, but they have not been measured yet in PD patients with PS (PDPS) to assess a potential vestibular impairment.
Materials and Methods. We enrolled 15 PD patients, 15 PDPS patients, and 30 healthy controls (HCs). +ey underwent
neurological examination and were examined with Uniﬁed Parkinson’s Disease Rating Scale II-III (UPDRSII-III), audiovestibular
workup, and cVEMP recordings. Data were analysed with Chi-square, one-way ANOVA, multinomial regression, nonparametric,
and Spearman’s tests. Results. cVEMPs were signiﬁcantly impaired in both PD and PDPS compared with HCs. PDPS exhibited
more severe cVEMP abnormalities with prevalent bilateral loss of potentials, compared with the PD group, in which a prevalent
unilateral loss was instead observed. No clinical-neurophysiological correlations emerged. Conclusions. Diﬀerently from HC,
cVEMPs are altered in PD. Severity of cVEMPs alterations increases from PD without PS to PDPS, suggesting an involvement of
vestibulospinal pathway in the pathophysiology of PS. Our results provide evidence for a signiﬁcant impairment of cVEMPs in
PDPS patients and encourage further studies to test validity of cVEMPs as diagnostic and prognostic biomarkers of
PD progression.
1. Introduction
Parkinson’s disease (PD) is a common neurodegenerative
disease characterized by both motor and nonmotor fea-
tures. While motor signs (tremor, rigidity, and bradyki-
nesia) mainly originate from the loss of dopaminergic
neurons of substantia nigra pars compacta (SNpc) [1, 2], the
pathophysiology of the large cohort of symptoms com-
plicating the disease course, such as postural impairment,
remains unclear, although it has been ascribed to the
progressive degeneration of other cortical and subcortical
structures [1].
Pisa syndrome (PS) is a peculiar postural complication,
consisting in a persistent lateral trunk ﬂexion (LTF) of more
than 10° that can be reduced by passive mobilization or
supine positioning, occurring throughout the disease course
but favoured by the longer disease duration and responsible
for severe disability [3–5]. Neurochemical imbalance in the
basal ganglia homeostasis, defective sensory-motor in-
tegration, abnormal body scheme perception, together with
a peripheral involvement consisting in myopathy, and other
musculoskeletal aﬀections have been proposed to contribute
to the pathophysiology of PS [3, 6, 7]. However, the precise
mechanisms have not been clariﬁed yet.
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Recently, a renewed interest emerged for vestibular
evoked myogenic potentials (VEMPs), utilized for testing
short-latency myogenic responses evoked by sound stim-
ulation of vestibular system [8]. Speciﬁcally, cervical ves-
tibular evoked myogenic potentials (cVEMPs) represent
the sternocleidomastoid (SCM) muscle response to sound
activation of saccule and signal transmission via the ves-
tibulospinal tract. +us, cVEMPs are a simple and reliable
tool to explore the activity of the vestibulocollic reﬂex,
linking the VIII and XI cranial nuclei, thereby representing
an index of brainstem integrity [9–12]. Indeed, the ves-
tibular system has been involved in the pathophysiology of
PS [13], as well as in falls and other motor complications of
advanced PD [13–15].
In spite of such evidence, to date, few studies addressed
these issues in PD population. Evidence has been provided
for the loss of muscular potentials, in the absence of clear
correlations with relevant clinical features, such as disease
duration and severity, gait, or sleep disturbances [15–17].
However, cVEMPs measurement has not been utilized yet to
evaluate vestibular involvement in PS.
In this study, we recorded cVEMPs to assess vestibular
integrity in PD patients with PS (PDPS) compared with both
PD patients without PS and healthy controls (HCs).
2. Materials and Methods
2.1. Materials. A total of 60 subjects were consecutively
recruited at the movement disorders outpatient service, Tor
Vergata University Hospital, Rome, Italy, between 2015 and
2017. Subjects were divided into 3 groups: PD patients
(n � 15), PD patients with PS (PDPS, n � 15), and healthy
controls (HC, n � 30). Idiopathic PD was diagnosed
according to the British Parkinson’s Disease Society Brain
Bank criteria and conﬁrmed by DaTscan [18]; PDPS patients
showed trunk lateral ﬂexion of at least 10°measured with
a wall goniometer, alleviated by passive mobilization or su-
pine positioning, according to recent diagnostic criteria [3].
HCs were healthy age-matched control subjects recruited
from nonblood relatives of PD patients who did not show any
neurological sign.
Exclusion criteria included dementia (MMSE score <24),
cervical herniation, history of orthopaedic diseases (such as
scoliosis), major spinal surgery, improper neck movements
that could alter audiological assessment, middle ear diseases,
hearing thresholds exceeding 50 dBHL, and medical therapy
potentially interfering with vestibular function or potentially
able to induce PS (e.g., neuroleptics).
All patients were evaluated by a movement disorder
specialist, with Uniﬁed Parkinson’s Disease Rating Scale
(UPDRS) Sections II and III and Hoehn and Yahr scale (H &
Y). Medical therapy was accurately recorded, and total
levodopa equivalent daily dose (LEDD) was calculated for
each patient.
All enrolled subjects underwent audiological workup to
exclude hearing impairment, which could alter VEMPs
recording. +en, cVEMPs were recorded, as described be-
low. +e entire assessment was performed in “on-therapy”
state.
+e study was conducted in agreement with ethical
principles of Helsinki declaration. Informed consent was
obtained from all participants.
2.2. Procedures
2.2.1. cVEMPs Recording. +e test was performed in
a hypoechoic room, with the patient lying down on an
examination bed, head positioned at 30°. Five surface
electrodes were placed, the negative ones on the medium
third of SCM muscles bilaterally, the positive ones in the
centre of claviculae, and the ground electrode on the ster-
num. While maintaining tonic contraction of SCM, a bi-
lateral acoustic stimulation (alternate click) was given to the
subject continuously for 30 s, at a frequency of 4Hz, du-
ration of 100 μs and at an intensity of 135 dB SPL, similarly
in the three groups. +e compound muscle action potentials
(CMAPs) were then recorded as described [9].
Although muscle tonic activation was not measured, it
was continuously monitored by visual feedback to assist the
subject in maintaining the task. +e recorded signals were
ampliﬁed, averaged, and band-pass ﬁltered (10–500Hz).+e
procedure was performed at least twice to ensure re-
producibility; grand average was analysed. CMAPs were
evaluated qualitatively (present/absent) and quantitatively,
measuring wave latencies and peak amplitudes from stim-
ulus onset to the peak of the initial positivity (P13) and
subsequent negativity (N23) [9]; interpeak latencies were
also calculated [11] (Figure 1).
2.2.2. Audiological Workup. Each subject underwent an
otolaryngologic evaluation, including otoscopic examina-
tion, acoustic impedance test and pure-tone audiometry
(PTA) to exclude middle ear disorders. Hearing loss was
estimated bilaterally and for each pure-tone frequency
stimulation (from 125 to 8000Hz). +e intensity threshold
of the acoustic reﬂex was determined for each ear using
500Hz, 1000Hz, 2000Hz, and 4000Hz stimulus tones. +e
stimulus was presented either to the same ear as the com-
pliance probe (ipsilateral reﬂex) or to the opposite ear
(contralateral reﬂex).
For the Brainstem Auditory Evoked Responses (BAER)
assessment, the active electrode was mounted to the middle of
the forehead “Fpz,” the reference electrode to the ipsilateral
mastoid “M1,” and the ground to the contralateral one “M2.”
+e test procedures followed the Sininger protocol [19].
Analysis of BAER was done quantitatively to assess the ab-
solute latencies of waves I, III, and V and interpeak latencies
of these waves (I–III, III–V, and I–V). Qualitative analysis of
the waveform morphology included the subjective judgment
on the shape and the quality of the waveforms.
2.3. Statistical Analysis. Diﬀerences among groups in cat-
egorical variables were calculated using the Chi-square test.
Audiometric data were assessed separately by Kruskal–
Wallis test for multiple comparisons and Wilcoxon test for
repeated measures, as they were nonnormally distributed.
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e one-way ANOVA test with Bonferroni correction was
performed for cVEMPs amplitude and latencies analysis
among groups.
Correlations between neurophysiological parameters
(unilateral or bilateral absence of cVEMPs, their amplitudes
and latencies) and clinical features (disease duration, age of
onset, UPDRS II-III as total scores and single subitems,
degrees of LTF, and bending side) were assessed with
Spearman’s test. Moreover, after testing dierences in
cVEMPs alterations within the groups, the association be-
tween vestibular dysfunction and clinical presentation of PD
was further assessed by means of multinomial logistic re-
gression, using disease duration as covariate.
e level of statistical signicance (p value) was set at
0.05. Statistical analyses were performed using the SPSS
version 21 for Mac (SPSS Inc., Chicago).
3. Results
Main demographic, clinical, and neurophysiological data are
summarized in Table 1.
Groups did not signicantly dier in age, gender, and
auditory testing (auditory thresholds and BAER latencies,
data not shown). Disease duration, UPDRS part II-III scores,
and LEDD were signicantly higher in PDPS than in PD
(respectively, p< 0.001, p< 0.001, p< 0.001, and p  0.013).
Conversely, no dierence emerged in the prevalence of
dopaminergic medications used in PD and PDPS groups;
specically, 11/15 PD patients and 9/15 PDPS patients were
on dopamine agonists, 10/15 PD and 9/15 PDPS were on
MAO-B inhibitors, and 12/15 PD and 13/15 PDPS were on
levodopa.
Consistent with previous ndings, the main alteration
we observed in cVEMPs within the PD groups was the
unilateral or bilateral absence of evoked potentials (Fig-
ure 1); even if PDPS and PD patients had longer P13 and
N23 latencies, no signicant dierences emerged among
other analysed variables.
Table 1 shows, for each group, the percentage of “nor-
mal,” “unilateral absence,” and “bilateral absence” of
cVEMPs. Chi-square analysis demonstrated that normal
cVEMPs were signicantly reduced in both PD and PDPS
compared with HC (respectively, p< 0.001 and p< 0.001).
However, the pattern of cVEMP abnormalities signicantly
diered between PDPS and PD (p< 0.0001), with PDPS
showing lower normal responses (p< 0.05) and more fre-
quent “bilateral absence” (p< 0.001); otherwise “unilateral
absence” was more common in PD than in PDPS (p< 0.05)
(Figure 2).
Multinomial logistic regression showed that “unilateral
absence” of cVEMPs but not “bilateral absence” is signi-
cantly associated with pure PD condition (T  21.9,
p< 0.001), independently from disease duration. Moreover,
either “unilateral” or “bilateral” cVEMPs absence are directly
associated with PDPS condition (respectively, T  3.4, p 
0.02 p  0.02 and T  21.2, p< 0.001), as well as disease
duration (T  0.4, p  0.004).
Finally, correlation analysis between neurophysiological
and clinical parameters did not provide any signicant result
among the groups.
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Figure 1: cVEMP recording in normal (a) and altered (b) conditions. In both (a) and (b) boxes, the two traces correspond, respectively, to
right and left SCM muscle potential evoked by bilateral sound stimulation. P13 represents the potential’s rst peak of positivity, N23 the
subsequent peak of negativity. In (a), cVEMPs are present bilaterally; in (b), cVEMP is lost on the right side.
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4. Discussion
e neuropathological hallmark of PD is the ascending
accumulation of α-synuclein immunoreactive Lewy bodies
(LB) from SNpc and other brainstem structures to superior
brain areas; however, LB deposition has been recently
demonstrated in all brainstem ber tracts and cranial nerve
nuclei, including the vestibular system [20]. Of note, do-
pamine, whose levels are critically reduced in PD, is a fun-
damental modulator of vestibular nuclei function [21].
cVEMPs are now considered a reliable tool to assess ves-
tibular and brainstem functions in distinct neurological
disorders, including neuroaudiological, demyelinating and
cerebrovascular diseases, migraine, and CNS tumours
[8, 22]. Conversely, few studies examined the potential
utilization of cVEMPs as a tool to monitor neurodegener-
ative diseases, particularly PD [15].
In our cross-sectional analysis of cVEMPs among PDPS,
PD patients without PS and HCs without neurodegenerative
conditions, we demonstrate that PD patients, compared with
the latter group, have signicantly abnormal vestibular
evoked responses, consisting in unilateral or bilateral loss of
cVEMPs. Furthermore, our ndings indicate that the neu-
rophysiological prole diers between PD patients with and
without PS. e PD group mostly exhibits the unilateral
absence of cVEMPs, whereas the PDPS group shows
prevalently bilateral loss of responses. Our data on vestibular
dysfunction may thus re£ect the progression of brainstem
neurodegeneration along disease course, with a progressive
worsening in advanced stages, when postural complications
are more frequently observed [23].
Despite the absence of signicant correlations between
neurophysiological parameters and specic clinical features,
our results show a peculiar alteration of vestibular func-
tioning in PS. While a previous study demonstrated uni-
lateral peripheral vestibular hypofunction, ipsilateral to the
LTF side [13], we observed a higher prevalence of bilateral
alterations in PDPS patients here. A note of caution in the
interpretation of our data is required, as our study lacks
peripheral testing, which might have been useful in the
anatomoclinical correlation. However, combining existing
data with our novel observations, we hypothesize that
central vestibular impairment might concur with peripheral
dysfunction in patients with PS [13], suggesting the specic
frailty of the vestibular system in this condition, even if
longer disease duration might also play a role.
e study also included an audiometric examination of
the three groups, which showed no signicant dierences in
the hearing thresholds of subjects with PD, PDPS, and HCs.
is nding partially disagrees with evidence by Vitale and
colleagues [24, 25], instead demonstrating the occurrence of
neurosensory hearing impairment in PD patients. e ex-
clusion, in our study, of subjects with hearing thresholds
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Figure 2:e plot summarizes the percentage of dierent cVEMPs
responses in the three groups. Signicance markers (∗  p< 0.05;∗∗  p< 0.001) refer to the presence of “normal responses.” Other
data are expressed in the text.
Table 1: Clinical and electrophysiological data (y  years; M  males; F  females; mg  milligrams; ms  millisecond; mcV  microVolt;
LTF  lateral trunk £exion; R  right; L  left; LEDD  levodopa equivalent daily dose; n.s.  statistically nonsignicant). Data are expressed
as mean ± standard deviation (SD).
PDPS (n  15) PD (n  15) HC (n  30)
Age (y) 73.3 ± 3.6 69.6 ± 7.11 69.36 ± 6.67 n.s.
Gender (M/F) 8/7 7/8 15/15 n.s.
Disease duration (y) 8.7 ± 4.4 4.6 ± 3.83 — p< 0.001
UPDRS II 12.4 ± 2.8 6.2 ± 3 — p< 0.001
UPDRS III 30 ± 6.1 18.9 ± 6.1 — p< 0.001
LTF (°) 21 ± 9 — —
Side of LTF (R/L) 7/8 — —
LEDD (mg) 814 ± 275 369 ± 202 — p  0.013
Normal cVEMPs 48% 68% 97% p< 0.001
Unilateral absence of cVEMPs 12% 26% 0% p< 0.001
Bilateral absence of cVEMPs 40% 6% 3% p< 0.001
P13 latencies (ms) 17.8 ± 10.82 14.32 ± 3.3 16.07 ± 8.97 n.s.
N23 latencies (ms) 26.53 ± 10.28 22.68 ± 4.2 25.77 ± 10.48 n.s.
P13 amplitudes (mcV) 46.18 ± 29.88 41.92 ± 37.75 40.57 ± 26.1 n.s.
N23 amplitudes (mcV) −44.9 ± 35.26 −54.6 ± 34.01 −63.16 ± 42.31 n.s.
Interpeak latencies (ms) 8.6 ± 2.5 8.5 ± 2.3 9.6 ± 3.4 n.s.
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over 50 dBHL even at a single frequency and additionally the
smaller sample size and the diﬀerent clinical-demographic
features of the cohorts may account for this discrepancy.
5. Conclusions
cVEMPs are a noninvasive and inexpensive test exploring
vestibulospinal tract, a crucial pathway for postural control.
Despite the small sample size, here we observed that ves-
tibulospinal dysfunction progresses in PD, with a milder
involvement (unilateral loss of cVEMPs) in the absence of
postural disabilities and more severe alterations (bilateral
loss of cVEMPs) in the presence of PS.+erefore, we suggest
that a major impairment of vestibular system might be
involved in pathophysiology of PS, probably mirroring more
advanced brainstem pathology in parallel with a longer
disease duration. Further prospective studies on larger
samples are mandatory to understand the associations be-
tween audiovestibular dysfunction and clinical progression
of PD, allowing to establish the potential usefulness of
cVEMPs as diagnostic and prognostic biomarkers for PD.
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